$50.47
1.43% yesterday
Nasdaq, Jun 06, 10:00 pm CET
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Sanofi Sponsored ADR Stock price

$50.47
-2.68 5.04% 1M
+2.01 4.15% 6M
+2.24 4.64% YTD
+0.96 1.94% 1Y
-0.34 0.67% 5Y
+0.97 1.96% 10Y
+6.08 13.69% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.71 1.43%
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Key metrics

Market capitalization $122.20b
Enterprise Value $137.15b
P/E (TTM) P/E ratio 4.29
EV/Sales (TTM) EV/Sales 1.31
P/S ratio (TTM) P/S ratio 1.17
P/B ratio (TTM) P/B ratio 0.75
Dividend yield 4.38%
Last dividend (FY25) $2.21
Revenue (TTM) Revenue $104.85b
EBIT (operating result TTM) EBIT $23.51b
Cash position $9.15b
EPS (TTM) EPS $11.76
P/E forward 13.37
P/S forward 2.35
EV/Sales forward 2.63
Short interest 0.17%
Show more

Is Sanofi Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Sanofi Sponsored ADR forecast:

20x Buy
77%
6x Hold
23%

Analyst Opinions

26 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy
77%
Hold
23%

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
104,850 104,850
-
100%
- Direct Costs 30,956 30,956
-
30%
73,894 73,894
-
70%
- Selling and Administrative Expenses 22,157 22,157
-
21%
- Research and Development Expense 16,581 16,581
-
16%
27,730 27,730
-
26%
- Depreciation and Amortization 4,224 4,224
-
4%
EBIT (Operating Income) EBIT 23,506 23,506
-
22%
Net Profit 14,519 14,519
-
14%

In millions USD.

Don't miss a Thing! We will send you all news about Sanofi Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Sponsored ADR Stock News

Neutral
GlobeNewsWire
3 days ago
Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries.
Neutral
Business Wire
4 days ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing,...
Neutral
GlobeNewsWire
4 days ago
ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusion Studies used Enable Injections' enFuse® on-body injector, an automated hands-free i...
More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 82,878
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today